HeartBeam Completes ALIGN-ACS Enrollment, Eyes FDA Pivotal Study
BEAT is trading near its 52-week low of $0.355 (4.2% above the low).
Summary
HeartBeam has completed enrollment in its ALIGN-ACS study ahead of schedule and will present results at TCT 2026. The company also advanced HEADSTART-ACS enrollment and submitted a pre-submission to the FDA for a pivotal MI study. Its 12-lead patch is progressing toward FDA clearance, with commercialization planned through a strategic partner. These updates follow a period of financial strain, including a going concern warning and a Nasdaq bid price deficiency. The rapid enrollment and regulatory progress could improve the company's outlook, but the stock remains near its 52-week low at $0.37.
At the time of this announcement, BEAT was trading at $0.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.3M. The 52-week trading range was $0.36 to $4.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.